EHA Immunotherapy Program

Description

5-course program on immunotherapy in hematological malignancies

Want to know more?

This five-course program on immunotherapy in hematological malignancies addresses innovative approaches to directly targeting tumor antigens by monoclonal antibodies (including bi-specific and tri-specific antibodies and drug-conjugates) and to generate anti-tumor cellular products, such as NK-CAR cells and allo-CAR-T cells. The future role of combining treatments triggering the immune system and the regulatory and ethical aspects of immunotherapy are also discussed. The courses include interactive quizzes, links to video clips of experts, and suggestions for additional reading. The Immunotherapy Program is complimented by the EHA CAR-T Program. This program has been peer-reviewed by : Professor Ulrich Jäger, Professor John Gribben and Professor Marie Jose Kersten. Current courses: 
– Tumor Antigen-Targeting Monoclonal Antibodies
– Ethics and Consent (in common with the CAR-T Program)
– Regulatory Aspects of Immunotherapy (in common with the CAR-T Program)
– Cell Therapy